药学干预改进国家重点监控药品使用的实践及效果分析  

Practice and Effect Analysis of Pharmaceutical Intervention to Improve Use of National Key Monitored Drugs

作　　者：张美玲[1] 赵云[2] ZHANG Mei-ling;ZHAO Yun(Tongde Hospital of Zhejiang Province;Taizhou Enze Medical Center(Group)Taizhou Hospital)

机构地区：[1]浙江省立同德医院 [2]浙江台州医院

出　　处：《医院管理论坛》2021年第4期56-60,共5页Hospital Management Forum

基　　金：北京医卫健康公益基金会医学科学研究基金,编号:180207-B186010。

摘　　要：目的加强医疗机构对国家重点监控药品的管理,促进临床医生合理、经济使用药物,减轻患者药品负担。方法建立国家重点监控药品点评制度及标准,制定监管措施和考核方案,分析监管前后指标变化,探寻适合本院的监管办法。结果监管制度实施后,医院国家重点监控药品使用金额比监管前降低53.49%,重点监控药品金额占医院药品比重从5.78%下降至3.25%,出院患者人均药品费用下降36.75%,出院患者人均重点监控药品费用下降64.45%。结论医院实行重点监控药品点评制度能够保障药品在临床安全合理使用的同时,有效降低重点监控药品的使用金额和药占比重,减轻患者的药品费用负担。Objective To strengthen the management of national key monitored drugs by medical institutions, promote the rational and economic use of drugs by clinicians, and reduce the burden of drugs on patients. Methods A national key monitoring drug review system was established. Standards, regulatory measures and assessment plans were formulated. Changes in indicators before and after regulation were analyzed, and regulatory methods suitable for this hospital were explored. Results After the implementation of the supervision system, the amount of national key monitored drugs used in hospitals was reduced by 53.49% compared with before supervision. The amount of key monitored drugs in the proportion of hospital drugs decreased from 5.78% to 3.25%. The per capita drug costs of discharged patients decreased by 36.75%, and the per capita key monitored drugs cost of discharged patients dropped by 64.45%. Conclusion The implementation of a review system for key monitored drugs in hospitals can ensure the safe and reasonable use of drugs in clinical practice, while effectively reducing the cost and proportion of key monitored drugs used and reducing the burden of drug costs on patients.

关 键 词：国家重点监控药品 药学干预 合理用药 监管 

分 类 号：R194[医药卫生—卫生事业管理]